Impact of Inflammatory Bowel Disease on Survival and Risk of Retransplantation of Primary Sclerosing Cholangitis Patients Following Liver Transplantation: UNOS Data Analysis.
1Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL
2Transplant, Mayo Clinic, Jacksonville, FL
Meeting: 2017 American Transplant Congress
Abstract number: B193
Keywords: Liver, Primary sclerosing cholangitis, Retransplantation, Survival
Session Information
Session Name: Poster Session B: Liver Retransplantation and Other Complications
Session Type: Poster Session
Date: Sunday, April 30, 2017
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall D1
Background: The impact of inflammatory bowel disease (IBD) on outcomes after liver transplantation (LT) for primary sclerosing cholangitis (PSC) has been inconclusive. Previous reports suggested that patients with IBD who undergo LT for PSC may have increased risk for adverse outcomes including retransplantation. The impact of IBD on patient survival in the United Network for Organ Sharing (UNOS) database has not been previously reviewed.
Objectives: To evaluate survival and risk of retransplant of patients who underwent LT for PSC, with and without inflammatory bowel disease (IBD).
Methods: We examined the UNOS database and identified patients with PSC who underwent LT between 1988 and 2016. PSC patients greater than 18 years of age were included. Kaplan-Meier survival analysis and log-rank tests were performed.
Results: In the UNOS database, 5% (7804/146,430) of patients underwent LT for PSC between Jan 1, 1988 and Oct 31, 2016. Mean age 45.3 years (SD±14.1), mean BMI 24.6 (SD± 4.8), males 5283 (68%), white 6406 (82%).
73% of PSC patients had IBD. 41% (N=3216) had ulcerative colitis (UC) and 13% (N=998) had crohn's disease. 39% (N=3,057) did not have IBD. Data regarding recurrence of PSC was available in 13% of PSC cases, and PSC recurrence occurred in 28.7% (299/1041).
There was no statistical difference in patient survival or retransplant rate between PSC patients with UC, crohn's disease, other colitis or without IBD (Log-rank test, p = 0.71). 
Conclusions: Analysis of the UNOS database showed that the presence of ulcerative colitis or crohn's disease or the absence of IBD in patients who underwent liver transplantation for PSC, did not have a significant impact on patient survival or the risk of retransplantation.
CITATION INFORMATION: Mousa O, Patel N, Corral J, Lee D, Nguyen J, Croome K, Harnois D. Impact of Inflammatory Bowel Disease on Survival and Risk of Retransplantation of Primary Sclerosing Cholangitis Patients Following Liver Transplantation: UNOS Data Analysis. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Mousa O, Patel N, Corral J, Lee D, Nguyen J, Croome K, Harnois D. Impact of Inflammatory Bowel Disease on Survival and Risk of Retransplantation of Primary Sclerosing Cholangitis Patients Following Liver Transplantation: UNOS Data Analysis. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/impact-of-inflammatory-bowel-disease-on-survival-and-risk-of-retransplantation-of-primary-sclerosing-cholangitis-patients-following-liver-transplantation-unos-data-analysis/. Accessed May 19, 2025.« Back to 2017 American Transplant Congress